Edition:
United States

Champions Oncology Inc (CSBR.OQ)

CSBR.OQ on NASDAQ Stock Exchange Capital Market

3.98USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,255
52-wk High
$4.75
52-wk Low
$2.22

Latest Key Developments (Source: Significant Developments)

Champions Oncology Reports Record Quarterly Revenue Of $5.2 Million
Thursday, 7 Dec 2017 04:15pm EST 

Dec 7 (Reuters) - Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY REPORTS RECORD QUARTERLY REVENUE OF $5.2 MILLION.Q2 REVENUE ROSE 16.7 PERCENT TO $5.2 MILLION.SEES FY 2018 REVENUE UP AT LEAST 20 PERCENT.CHAMPIONS BIOTECHNOLOGY INC - REITERATED EXPECTATIONS FOR FISCAL YEAR 2018 REVENUE GROWTH OF AT LEAST 20% OVER FISCAL YEAR 2017.CHAMPIONS BIOTECHNOLOGY INC - QTRLY LOSS PER SHARE $0.01.CHAMPIONS BIOTECHNOLOGY - REITERATES POSITION THAT "IT DOES NOT CURRENTLY INTEND TO RAISE CAPITAL IN THE EQUITY MARKET".  Full Article

Champions Biotechnology reports Q1 loss per share $0.06
Thursday, 14 Sep 2017 04:31pm EDT 

Sept 15 (Reuters) - Champions Biotechnology Inc :Champions Oncology reports record quarterly revenue of $5 million.Q1 revenue rose 37.1 percent to $5.0 million.Sees fy 2018 revenue up at least 20 percent.Champions Biotechnology Inc - reiterated expectations for fiscal year 2018 revenue growth of at least 20 pct over fiscal year 2017.Champions Biotechnology Inc qtrly loss per share $0.06.Champions Biotechnology Inc qtrly adjusted loss per share $0.01.  Full Article

Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of PDX models
Monday, 21 Aug 2017 08:30am EDT 

Aug 21 (Reuters) - Champions Biotechnology Inc :Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of patient-derived xenograft (PDX) models.Champions Biotechnology Inc- ‍cohorts of PDX models will be used in AstraZeneca's Oncology research and development programs in breast and lung cancer​.  Full Article

Champions Oncology to collaborate with Addario Lung Cancer Medical Institute
Friday, 18 Aug 2017 08:30am EDT 

Aug 18 (Reuters) - Champions Biotechnology Inc :Champions Oncology announces research collaboration with the Addario Lung Cancer Medical Institute to develop unique cohort of patient-derived xenograft (PDX) models.Champions Biotechnology - deal with Addario Lung Cancer Medical Institute "ALCMI" to develop a cohort of PDX models in patients with ROS1 gene rearrangement​.  Full Article

Norman Pessin reports 5.2 pct stake in Champions Oncology
Friday, 13 Jan 2017 09:46am EST 

Champions Biotechnology Inc : Norman Pessin reports 5.2 percent stake in champions Oncology Inc as of January 12 - sec filing .Norman Pessin - purchased Champions Oncology shares based on belief that shares, when purchased, were undervalued.  Full Article

Champions Oncology announces pricing of public offering of common stock
Thursday, 9 Jun 2016 07:30pm EDT 

Champions Oncology Inc : Offering 2 million registered shares of its common stock at an offering price of $2.25 per share .Champions Oncology Inc. announces pricing of public offering of common stock.  Full Article

No consensus analysis data available.